GCP
GRCE

GSA Capital Partners’s Grace Therapeutics GRCE Stock Holding History

GSA Capital Partners’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,774
Closed -$48K – 2243
2025
Q4 		$48K Buy
+13,774
New +$43.7K ﹤0.01% 1576

Other funds holding GRCE

Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

GSA Capital Partners's GRCE Position: Q1 2026 in Review

GSA Capital Partners sold out of Grace Therapeutics (GRCE) in Q1 2026, closing a stake of 13,774 shares — an estimated $48K sold.

GSA Capital Partners first reported a position in GRCE in Q4 2025 and held it in 1 quarter. The position peaked at $48K in Q4 2025. 34 funds tracked by Wall St. Rank hold GRCE as of Q1 2026.

  • GSA Capital Partners reported no remaining Grace Therapeutics position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 13,774 Grace Therapeutics shares in Q1 2026, an estimated $48K.
  • GSA Capital Partners first reported a position in Grace Therapeutics in Q4 2025 and held it in 1 quarter.
  • GSA Capital Partners's Grace Therapeutics position peaked at $48K in Q4 2025.
  • 34 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.